PAK 200

Drug Profile

PAK 200

Alternative Names: PAK 200S

Latest Information Update: 31 Jan 2008

Price : $50

At a glance

  • Originator Nissan Chemical Industries
  • Class Antineoplastics; Dihydropyridines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Reperfusion injury

Most Recent Events

  • 06 Apr 2001 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 06 Apr 2001 Preclinical development for Reperfusion injury in Japan (Unknown route)
  • 18 Aug 2000 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top